Mucosal immunization with PspA (Pneumococcal surface protein A)-adsorbed nanoparticles targeting the lungs for protection against pneumococcal infection

Rodrigues, Tasson C.; Oliveira, Maria Leonor S.; Soares‐Schanoski, Alessandra; Chavez-Rico, Stefanni L.; Figueiredo, Douglas Borges De; Gonçalves, Viviane Maimoni; Ferreira, Daniela M.; Kunda, Nitesh K.; Saleem, Imran; Miyaji, Eliane N.

doi:10.1371/journal.pone.0191692

Cited by 48 publications

(36 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, no binding to bacteria expressing PspA from clades 1 and 2 of family 1 was detected. In addition, immunizing the mucus membrane with NP/NCMP PspA4Pro was capable of inducing local and systemic antibodies that conferred partial protection against pneumococcus family 2 alone [146].…”

Section: Development Of Pneumococcal Nanovaccinesmentioning

confidence: 99%

Development of Next Generation Streptococcus pneumoniae Vaccines Conferring Broad Protection

et al. 2020

View full text Add to dashboard Cite

Streptococcus pneumoniae is a major pathogen causing pneumonia with over 2 million deaths annually, especially in young children and the elderly. To date, at least 98 different pneumococcal capsular serotypes have been identified. Currently, the vaccines for prevention of S. pneumoniae infections are the 23-valent pneumococcal polysaccharide-based vaccine (PPV23) and the pneumococcal conjugate vaccines (PCV10 and PCV13). These vaccines only cover some pneumococcal serotypes and are unable to protect against non-vaccine serotypes and unencapsulated S. pneumoniae. This has led to a rapid increase in antibiotic-resistant non-vaccine serotypes. Hence, there is an urgent need to develop new, effective, and affordable pneumococcal vaccines, which could cover a wide range of serotypes. This review discusses the new approaches to develop effective vaccines with broad serotype coverage as well as recent development of promising pneumococcal vaccines in clinical trials. New vaccine candidates are the inactivated whole-cell vaccine strain (Δpep27ΔcomD mutant) constructed by mutations of specific genes and several protein-based S. pneumoniae vaccines using conserved pneumococcal antigens, such as lipoprotein and surface-exposed protein (PspA). Among the vaccines in Phase 3 clinical trials are the pneumococcal conjugate vaccines, PCV-15 (V114) and 20vPnC. The inactivated whole-cell and several protein-based vaccines are either in Phase 1 or 2 trials. Furthermore, the recent progress of nanoparticles that play important roles as delivery systems and adjuvants to improve the performance, as well as the immunogenicity of the nanovaccines, are reviewed.

show abstract

Section: Development Of Pneumococcal Nanovaccinesmentioning

confidence: 99%

Development of Next Generation Streptococcus pneumoniae Vaccines Conferring Broad Protection

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Furthermore, they successfully developed a NPMPs loaded with pneumococcal surface protein A (PspA) as DPI vaccine against pneumococcal infection that successfully induced antibody response against in vitro DCs line [50]. Recently, this work was continued by Rodrigues et al, which demonstrated successful vaccination antibody production through in vivo study via lung instillation in mice compared to subcutaneous injection [51]. …”

Section: Aerosolized Delivery Strategies For Macromolecule Drug Deliverymentioning

confidence: 99%

Carriers for the targeted delivery of aerosolized macromolecules for pulmonary pathologies

Osman

Kaneko

Carini

et al. 2018

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Introduction: Macromolecules with unique effects and potency are increasingly being considered for application in lung pathologies. Numerous delivery strategies for these macromolecules through the lung have been investigated to improve the targeting and overall efficacy.Areas covered: Targeting approaches from delivery devices, formulation strategies and specific targets are discussed.Expert opinion: Although macromolecules are a heterogeneous group of molecules, a number of strategies have been investigated at the macro, micro, and nanoscopic scale for the delivery of macromolecules to specific sites and cells of lung tissues. Targeted approaches are already in use at the macroscopic scale through inhalation devices and formulations, but targeting strategies at the micro and nanoscopic scale are still in the laboratory stage. The combination of controlling lung deposition and targeting after deposition, through a combination of targeting strategies could be the future direction for the treatment of lung pathologies through the pulmonary route.

show abstract

“…To replace a mix of 13 to 20 serotypes of pneumococcus, Butantan developed a vaccine based on recombinant pneumococcal surface protein A (PspA) from three different strains, making production easier and less expensive [40][41][42].…”

Section: Pneumococcal Vaccinementioning

confidence: 99%

Developing Countries Can Innovate and Produce Vaccines: The Case of Butantan in Brazil

Raw¹

2019

Vaccines - The History and Future

View full text Add to dashboard Cite

Since the introduction of vaccines, governments learn that they are the most efficient and inexpensive tool to avoid the spreading of infectious diseases. It resulted in the creation of public research institutes to develop new vaccines, which gave birth to the vaccine industry, that is, growing in size by acquisition of competitors, which estimate that in 2019 they will sell $58 billion, where developing countries represent 80% of the world population, submitted to be dependent of production and prices from large producers. Incapable or not willing to assume the responsibility to produce, accept to purchase vaccines in bulk for filling and labeling as "producers." Butantan, a public not for profit institute became the first producer of specific anti-venoms and anti-rabies sera. In 1985, Butantan Center of Biotechnology attracted 25 young PhD, which accepted to carry on inovations and technical developments, setting dedicated plants to produce vaccines at affordable cost, aiming self-sufficiency to distribute free through the Ministry of Health. This chapter describes problems and solutions that must be faced to produce vaccine at a cost that developing countries can afford. Keywords: vacines control epidemics, developing coutries 80% of world population, developing countries self-sufficiency, Butantan from innovation to production, anti-venonms and anti-toxinas, encloses production plants, pertussis reduction by DTP vaccine, whole pertussis low in LPS, MPLA from B pertusis as adjuvant, MPLA adjuvant reduce ¼ influenza doses an price of vaccine, vitamines A,D,E, riboflavin as adjuvants, pneumococcus-PSAP3 reduce cost of pneumo vaccine, plasma fractions not for sale, lung surfactant saves neonatals 1. Institute Butantan-research, process development, and production 1.1 Antivenoms and antitoxins Antisnake venoms were the strength of Instituto Butantan and its priority [1-4]. At the New York World Fair, Vital Brazil saved the life of an employee of the Bronx Zoo bitten by a rattlesnake, which induced President Theodore Roosevelt pay a visit to Butantan in 1915. In 1983, Butantan sera production situation was scary: venoms were collected from snakes and administered to horses. The horses were bled and their blood collected in rusted milk drums, precipitated Vaccines-The History and Future 2 with ammonium sulfate, concentrated using a dirty towel, diluted and kept in large bottles until they "mature," and covered with mold! Probable other developing countries producers used the same ancient manufacturing process. Changing the production technology was the first goal of a recent Ph.D. group of researchers supported by the staff from the production laboratories under my supervision (Figures 1-6). The first idea was to replicate the milk industry profile, creating a "hands-off " fully enclosed system using large stainless steel tanks and an industrial plate centrifuge. After snake venom inoculation, horse blood was collected in a 7-liter sterile bag with anticlotting solution, stirred, and kept in a cold room overnight. ...

show abstract

Mucosal immunization with PspA (Pneumococcal surface protein A)-adsorbed nanoparticles targeting the lungs for protection against pneumococcal infection

Cited by 48 publications

References 32 publications

Development of Next Generation Streptococcus pneumoniae Vaccines Conferring Broad Protection

Development of Next Generation Streptococcus pneumoniae Vaccines Conferring Broad Protection

Carriers for the targeted delivery of aerosolized macromolecules for pulmonary pathologies

Developing Countries Can Innovate and Produce Vaccines: The Case of Butantan in Brazil

Contact Info

Product

Resources

About